follow ep
unchang ep guidanc weight back half
year continu top-line weak outlook
unchang post ep remain uw view
valuat in-lin peer expens given lower
ep weak top-line reiter guidanc stock
trade vs despit profit beat unchang
guidanc post manag guid earlier month see note
analyst day takeaway linger top-line weak organ sale vs
consensu set high bar need growth inflect hit fy
guidanc view ep guidanc achiev fx pressur
flex vs manag guidanc ep fall high end
manag rang support strong margin
perform nonetheless see challeng road ahead organ sale
growth meet manag guidanc achiev requir
sequenti acceler average organ growth bp
remaind year follow weak remain uw chang pt
see in-lin valuat peer expens consid weaker
top-line trajectori organ sale growth pg vs
name trade price-to-earnings
detail call note top prioriti reinvigor growth
trash bag wrap charcoal categori face
challeng term distribut loss widen price gap top-line
growth improv expect second half fiscal year easier
comparison rebuild distribut organ sale growth
slightli improv off-set report basi weaker fx also
highlight grow spread track untrack channel
still believ overal market share yoy gross margin beat
posit quarter attribut easi comparison robust
cost save continu guid slightli gm year
reflect addit suppli chain invest tougher comparison go
number report ep cent consensu
mse driven gross margin out-performance upsid
profit line offset top-line downsid top-line miss consensu
household person unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
organ sale declin yoy consensu although
weak telegraph analyst day note household segment
materi under-perform report sale yoy due wide price gap
distribut loss bag wrap categori gross margin howev
outperform bp yoy expans bp ahead consensu
benefit combin price cost save partial off-set
higher trade promot manufacturing/logist cost result
gross profit beat vs consensu sg came slightli higher
expect sell administr cost bp yoy sale
bp ahead mse advertis cost rose bp yoy came
bp ahead mse oper profit nonetheless beat consensu
oper margin came bp ahead consensu
oper profit line lower expect tax rate ad cent upsid vs
project support cent overal ep upsid vs mse round
sale growth segment clean segment organ sale decreas yoy
strength profession product off-set weak
laundri well unfavor mix strong growth
essenti top-line downsid versu model distribut loss
wider price gap glad trash bag well higher trade promot
spend prepar grill season charcoal lifestyl
segment organ sale increas driven dd growth burt bee
innov face lip solid strength brita
organ sale grew estim support growth latin america
ep guidanc reiter reiter ep guidanc
vs consensu mse follow recent guid
analyst day continu expect mute organ sale growth
report sale guid -lsd declin affect point fx
headwind gross margin slightli spite bp yoy
expans quarter line item guidanc includ expect
sale unchang line mse ii sell administr
cost sale sale unchang line mse iii
tax rate unchang line mse ep estim
clx mute organ sale growth neg
clx mute organ sale growth neg
emerg portfolio
emerg portfolio
hpc skew low-growth product
categori high exposur us
face signific competit
pressur limit lt top-line potenti
vs peer view short-term wider
price gap driven increas share loss
shrink distribut creat
top-line risk well margin risk
ev/ebitda
price-to-earnings high consid limit lt ep
growth strateg potenti well
risk achiev price
risk includ top-line margin upsid
improv price better expect
consolid potenti cost-cut
deriv base case
profit upsid drive multipl expans top-line margin upsid bp
better expect volum bp margin upsid declin
commod cost upsid cost-cut drive multipl expans
bull case ep
lower long-term ep growth peer limit upsid forecast lt
organ top line growth bp averag margin expans expect
valuat ep roughli one half standard deviat
averag reflect competit risk portfolio
fundament weaken challeng us hpc environ drive bp us
price downsid coupl bp volum downsid market share
pressur bp margin reinvest busi multipl
compress bear case ep
exhibit bear bull commod price risk/reward driver
valu
bp
million
million except ep
product sold
net sale
chang bp
net sale
chang bp
sell administr
net sale
chang bp
total sale
chang bp
total sale
chang bp
net sale
chang bp
net sale
net earn cont op
net sale
ep continu op
asset held sale
net properti plant equip
note loan payabl
current matur lt debt
accru liabil
common stock apic
accumul comprehens loss
total liabil stockhold equiti
depreci amort
chang a/l
accru liabil
net cash discontinu oper
net cash oper
net cash invest
purchas treasuri stock
net cash financ
effect fx chang cash
net chang cash
begin cash equival
end cash equival
valuat methodolog risk
pt forecast lt organ top line growth bp averag
margin expans expect valuat ep roughli one half
standard deviat averag reflect competit risk
upsid risk tax polici reform benefit us compani top-line margin upsid
improv price better expect volum declin commod cost consolid
potenti cost-cut
cost-cut lower market share weaker macro
